

**FORM PTO 1449**  
(REV 2-32)

**U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE**

File No. 99-16C1

Serial No.  
10/659,684

**INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use several sheets if necessary)

**Applicant(s):**

Julia E. Novak, Scott R. Presnell, Cindy  
A. Sprecher, Donald C. Foster, Richard  
D. Holly, Jane A. Gross, Janet V.  
Johnston, Andrew J. Nelson, Stacey R.  
Dillon, Angela K. Hammond

**Filing Date:**

November 15, 2002

**Group:** 1647

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
JS	A1	6,057,128	05/20/00	Donaldson et al.	435	69.1	03/17/98

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, etc.)**

JS	A2	Parrish-Novak et al., <i>Nature</i> 408: 57-63, 2000.
JS	A3	148966, Mara, WashU-HHMI Mouse EST Project, 1998.
JS	A4	Ngo et al., "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox," <i>The Protein Folding Problem and Tertiary Structure Prediction</i> , pp. 492-495, 1994.
	A5	Wells, "Aditivity of Mutational Effects in Proteins," <i>Biochemistry</i> 26(37):8509-8517, 1990.

**Examiner**

/Jegatheesan Seharaseyon/

**Date considered**

10/02/2006

**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO 1449  
(REV 2-32)


U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

File No. 99-16C1

Serial No.  
10/659,684

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)



Applicant(s):  
Julia E. Novak, Scott R. Presnell, Cindy  
A. Sprecher, Donald C. Foster, Richard  
D. Holly, Jane A. Gross, Janet V.  
Johnston, Andrew J. Nelson, Stacey R.  
Dillon, Angela K. Hammond

Filing Date:  
September 10, 2003

Group: ~~1644~~  
1647

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
JS	A1	10/456,262	06-06-03	Nelson et al.			
	A2	11/285,970	11/23/05	Yee			
	A3	11/346,580	02-02-06	Novak et al.			
	A4	2004-0009150	01-15-04	Nelson et al.			
	A5	2004-0260065	12/23/04	Novak et al.			
	A6	2005-0095223	05-05-05	Sivakumar et al.			
	A7	2005-0244930	11/03/05	Presnell et al.			
	A8	2005-0265966	12-01-05	Kindsvogel et al.			
	A9	2006-0134754	06/22/06	Chan et al.			
	A10	6,307,024	10/23/01	Parrish et al.			
	A11	6,605,272	08/12/03	Dillon et al.			
	A12	6,686,178	02-03-04	Dillon et al.			
	A13	6,929,932	08/16/05	Presnell et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
JS	A14	03/103589	12/18/03	WO			
	A15	04/032857	04/22/04	WO			
	A16	05/037306	04/28/05	WO			
	A17	99/61617	12/02/99	WO			
	A18	04/112703	12/29/04	WO			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, etc.)

JS	A19		Hill et al., "Cytokines: promoters and dampeners of autoimmunity," <i>Current Opinion in Immunology</i> , <i>Current Biology LTD 14(6):791-797</i> , 2002.
	A20		Clegg et al., "Therapeutic Opportunities for IL-21," <i>European Cytokine Network</i> vol. 14, no. Supplement 3, 2003.
	A21		Nelson, et al., "Interleukin 21 has anti-tumor activity in animal models without the toxicity of IL-2," <i>Procedures of the American Association for Cancer Research Annual Meeting</i> , vol. 44, July 2003.
	A22		Funaro et al., "Monoclonal antibodies and therapy of human cancers," <i>Biotechnology Advances</i> , Elsevier Publishing Barking, GB vol. 18 no. 5, 2000.

Examiner

/Jegatheesan Seharaseyon/

Date considered

10/02/2006

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.